Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 74.88
+1.38 (1.88%)
At close: Sep 12, 2025
SHA:688192 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 511.35 | 359.9 | 91.29 | - | 10.29 | - | Upgrade |
Other Revenue | - | - | - | - | - | 27.76 | Upgrade |
| 511.35 | 359.9 | 91.29 | - | 10.29 | 27.76 | Upgrade | |
Revenue Growth (YoY) | 73.43% | 294.25% | - | - | -62.95% | -32.32% | Upgrade |
Cost of Revenue | 22.7 | 11.84 | 7.66 | 3.65 | 12.93 | 26.56 | Upgrade |
Gross Profit | 488.65 | 348.06 | 83.63 | -3.65 | -2.65 | 1.2 | Upgrade |
Selling, General & Admin | 661.24 | 598.78 | 437.55 | 128.44 | 87.95 | 340.43 | Upgrade |
Research & Development | 746.66 | 721.16 | 801.15 | 660.87 | 583.67 | 423.94 | Upgrade |
Other Operating Expenses | 24.85 | -2.1 | -0.27 | -0.39 | 0.1 | 0.49 | Upgrade |
Operating Expenses | 1,433 | 1,318 | 1,239 | 788.9 | 671.73 | 764.84 | Upgrade |
Operating Income | -944.16 | -969.66 | -1,155 | -792.55 | -674.37 | -763.65 | Upgrade |
Interest Expense | -30.43 | -22.75 | -7.57 | -4.34 | -3.07 | - | Upgrade |
Interest & Investment Income | 2.62 | 2.24 | 3.64 | 2.53 | 3.65 | 3.89 | Upgrade |
Currency Exchange Gain (Loss) | -1.88 | -2.45 | -1.45 | 10.1 | -6.45 | -28.9 | Upgrade |
Other Non Operating Income (Expenses) | -0.08 | -0.07 | -0.04 | -0.03 | -0.08 | -0.33 | Upgrade |
EBT Excluding Unusual Items | -973.93 | -992.69 | -1,161 | -784.3 | -680.32 | -788.99 | Upgrade |
Gain (Loss) on Sale of Investments | 18.3 | 14.45 | 22.52 | 42.16 | 0.97 | 0.29 | Upgrade |
Gain (Loss) on Sale of Assets | 0 | - | -0.01 | 0.02 | - | 198.82 | Upgrade |
Other Unusual Items | 69.29 | 38.59 | 30.5 | 6.39 | 9.47 | 3.29 | Upgrade |
Pretax Income | -886.34 | -939.65 | -1,108 | -735.74 | -669.88 | -586.58 | Upgrade |
Income Tax Expense | 0.05 | 0 | 0.1 | 0.26 | - | 0.03 | Upgrade |
Earnings From Continuing Operations | -886.4 | -939.66 | -1,108 | -736 | -669.88 | -586.61 | Upgrade |
Minority Interest in Earnings | 7.83 | 93.7 | - | - | - | - | Upgrade |
Net Income | -878.57 | -845.96 | -1,108 | -736 | -669.88 | -586.61 | Upgrade |
Net Income to Common | -878.57 | -845.96 | -1,108 | -736 | -669.88 | -586.61 | Upgrade |
Shares Outstanding (Basic) | 424 | 415 | 407 | 404 | 360 | 360 | Upgrade |
Shares Outstanding (Diluted) | 424 | 415 | 407 | 404 | 360 | 360 | Upgrade |
Shares Change (YoY) | 3.17% | 1.83% | 0.70% | 12.29% | 0.07% | - | Upgrade |
EPS (Basic) | -2.07 | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 | Upgrade |
EPS (Diluted) | -2.07 | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 | Upgrade |
Free Cash Flow | -832.32 | -788.1 | -1,000 | -677.15 | -501.26 | -621.75 | Upgrade |
Free Cash Flow Per Share | -1.96 | -1.90 | -2.46 | -1.67 | -1.39 | -1.73 | Upgrade |
Gross Margin | 95.56% | 96.71% | 91.61% | - | -25.72% | 4.31% | Upgrade |
Operating Margin | -184.64% | -269.43% | -1265.43% | - | -6556.55% | -2750.82% | Upgrade |
Profit Margin | -171.81% | -235.05% | -1213.42% | - | -6512.85% | -2113.09% | Upgrade |
Free Cash Flow Margin | -162.77% | -218.98% | -1095.44% | - | -4873.51% | -2239.65% | Upgrade |
EBITDA | -905.49 | -930.08 | -1,114 | -753.85 | -636.97 | -733.83 | Upgrade |
EBITDA Margin | -177.08% | -258.43% | - | - | - | - | Upgrade |
D&A For EBITDA | 38.67 | 39.58 | 40.94 | 38.7 | 37.4 | 29.82 | Upgrade |
EBIT | -944.16 | -969.66 | -1,155 | -792.55 | -674.37 | -763.65 | Upgrade |
EBIT Margin | -184.64% | -269.43% | - | - | - | - | Upgrade |
Revenue as Reported | 511.35 | 359.9 | 91.29 | - | 10.29 | 27.76 | Upgrade |
Advertising Expenses | - | - | - | 1.94 | - | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.